Background. Staphylococcus aureus superinfection contributed to high morbidity during the 2009 H1N1 influenza epidemic. In this setting, co-infection with methicillin-resistant S. aureus (MRSA) is specifically associated with increased mortality in pediatric patients. The molecular pathogenesis of co-infection is poorly understood, precluding the development of preventive or therapeutic interventions. S. aureus α-toxin (Hla) is a key virulence factor in acute lung injury and a focus of anti-staphylococcal clinical trials. Whereas past studies suggest that humans develop Hla-specific antibody after invasive infection, data is lacking for the current MRSA epidemic in the context of influenza co-infection.
Methods. Quantitative in vitro assays measuring anti-Hla IgG and Hla-neutralizing activity were developed. In collaboration with the Pediatric Acute Lung Injury and Sepsis Investigators, sera from 57 severely-ill influenza patients admitted to pediatric intensive care units were prospectively collected and analyzed. Serial specimens were available for 34 children.
Results. Day 0 sera (indicating pre-or early disease exposure) displayed anti-Hla activity that spanned 1-2 orders of magnitude, with no difference in serologic activity in patients mono-infected with influenza versus those co-infected with either methicillin-sensitive (MS-) or MRSA. However, Hla-antibody significantly increased in those with MRSA co-infection (median 16-fold increase from baseline, p < 0.001 v. MSSA or influenza only). In some children, anti-Hla IgG and neutralization activity increased over 100-fold in 2 weeks.
Conclusion. Hla is a potent immunogen in influenza-S. aureus co-infection, consistent with toxin production early in disease. The observation of elevated anti-toxin titers in influenza-MRSA co-infected children suggests that toxin-mediated lung injury may exacerbate disease in this population, highlighting potential benefit from Hla-neutralization therapy in early influenza infection. These data provide impetus for ongoing studies to understand pathogen synergy, the role of Hla, and targeted disease interventions.
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